Table 3. Impact of CBCT-Based Novel Standard on Initial Tumor Staging and IDR.
| Initial Tumor Stage | Proportion of Preexisting HCCs in Initial CBCT-HA to IDR | ||||
|---|---|---|---|---|---|
| Based on Dynamic CT | Based on CBCT-Based Novel Standard | One-Year Follow-Up, % | Two-Year Follow-Up, % | ||
| Per Lesion | Per Person | Per Lesion | Per Person | ||
| Single HCC witdin Milan (n = 61) | Single HCC witdin Milan (n = 38) | 50.0 (4/8) | 57.1 (4/7) | 12.9 (4/31) | 28.6 (4/14) |
| Multiple HCCs witdin Milan (n = 17) | 83.3 (20/24) | 100 (15/15) | 47.8 (22/46) | 100 (17/17) | |
| Multiple HCCs beyond Milan (n = 6) | 92.3 (24/26) | 100 (6/6) | 79.1 (34/43) | 100 (6/6) | |
| Single HCC beyond Milan (n = 4) | Single HCC beyond Milan (n = 2) | 0 (0/2) | 0 (0/1) | 0 (0/5) | 0 (0/2) |
| Multiple HCCs beyond Milan (n = 2) | 66.7 (2/3) | 100 (2/2) | 25.0 (2/8) | 100 (2/2) | |
| Multiple HCCs witdin Milan (n = 24) | Multiple HCCs witdin Milan (n = 13) | 40.0 (2/5) | 50.0 (2/4) | 45.5 (5/11) | 62.5 (5/8) |
| Multiple HCCs beyond Milan (n = 11) | 91.5 (54/59) | 100 (8/8) | 80.7 (67/83) | 100 (11/11) | |
| Multiple HCCs beyond Milan (n = 10) | Multiple HCCs beyond Milan (n = 10) | 66.7 (14/21) | 85.7 (6/7) | 48.3 (14/29) | 75.0 (6/8) |
| Total (n = 99) | - | 81.1 (120/148) | 86.0 (43/50) | 57.8 (148/256) | 75.0 (51/68) |
IDR = intrahepatic distant recurrence